Testosterone therapy
Prescription · Evidence and recent research
Notify me when meaningful evidence changes.
Where things stand
Testosterone therapy is intended for defined medical circumstances, not as a general longevity treatment. In 2025, the FDA revised cardiovascular warnings after the TRAVERSE trial and required warnings about increased blood pressure. This illustrates why evidence must be tied to the treated population: reassuring findings for one outcome do not prove anti-ageing benefit or eliminate other risks. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.
AI-written overview · not expert-reviewed · Background sources checked Sep 23, 2026 · Recent updates cover the last 30 days of this collection. A new report does not automatically change the evidence assessment.
⚠ Prescription or off-label use
Prescription hormone therapy requiring monitoring. Not an anti-ageing treatment.
Background and coverage
FDA: 2025 testosterone labeling update ↗
- Regulatory status
- Approved for indication
- Availability
- Prescription only
- Category
- Prescription
- Human results verified here
- 0
Evidence collection is needs review. 0 approved assessments; 64 assessments awaiting review; 0 published studies with verified results. Safety: not assessed.
Recorded evidence activity (experimental)
A numeric breakdown will be available after baseline review. Safety is not yet assessed.
What changed
Evidence events affecting this intervention
Systematic review finds testosterone signaling affects cardiovascular disease through multiple mechanisms
This systematic review examined the relationship between androgens (particularly testosterone) and cardiovascular disease in aging adults. The authors surveyed the literature on testosterone's genomic and non-genomic signaling mechanisms in the cardiovascular system and reviewed evidence on how exogenous testosterone treatment and androgen deprivation therapy affect cardiovascular outcomes. The review identified associations between androgen levels and various cardiovascular conditions including cardiac hypertrophy, heart failure, atherosclerosis, aortic valve disease, and aneurysms.
Narrative review summarizes diagnostic criteria and treatment evidence for hypogonadism in aging men with comorbidities
This narrative review examined the prevalence, diagnosis, and management of male hypogonadism in older men, particularly in the context of obesity and cardiometabolic disorders. The authors searched PubMed for relevant literature on hypogonadism, aging, obesity, diabetes, and related comorbidities, selecting original research articles, systematic reviews, meta-analyses, and clinical guidelines. The review addresses unresolved questions about diagnostic thresholds, the relationship between testosterone decline and aging, and the impact of treatment on symptoms and long-term health outcomes in older men.
Assessment history
The 25 most recent recorded changes, including corrections and backfill
Human studies with verified results
No published human results verified in this collection yet
Animal and mechanistic evidence
No preclinical studies tracked yet
Claims
Testable statements and where the evidence stands